At the time of writing, BeiGene Ltd ADR [ONC] stock is trading at $238.11, up 3.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ONC shares have gain 8.39% over the last week, with a monthly amount glided 15.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 18, 2024, and set its price target to $288. Macquarie started tracking the stock assigning a Outperform rating and suggested a price target of $259 on September 12, 2023. Jefferies initiated its recommendation with a Buy and recommended $287 as its price target on August 17, 2023. Citigroup started tracking with a Buy rating for this stock on July 17, 2023, and assigned it a price target of $275. In a note dated June 30, 2023, Bernstein downgraded an Mkt Perform rating on this stock and revised its target price from $335 to $196.
For the past year, the stock price of BeiGene Ltd ADR fluctuated between $126.97 and $248.16. BeiGene Ltd ADR [NASDAQ: ONC] shares were valued at $238.11 at the most recent close of the market.
Analyzing the ONC fundamentals
According to BeiGene Ltd ADR [NASDAQ:ONC], the company’s sales were 3.32B for trailing twelve months, which represents an 28.20% jump.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 235.43 points at the first support level, and at 232.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 241.62, and for the 2nd resistance point, it is at 245.13.
Ratios To Look Out For
It is important to note that BeiGene Ltd ADR [NASDAQ:ONC] has a current ratio of 1.93. In addition, the Quick Ratio stands at 1.72. Considering the valuation of this stock, the price to sales ratio is 7.03, the price to book ratio is 7.39.
Transactions by insiders
Recent insider trading involved XIAOBIN WU, Officer, that happened on Feb 18 ’25 when 51921.0 shares were purchased. Chair, Scientific Advisory Brd, Wang Xiaodong completed a deal on Feb 04 ’25 to sell 41760.0 shares. Meanwhile, Chair, Scientific Advisory Brd Wang Xiaodong sold 41760.0 shares on Jan 07 ’25.
